

# Carlo Ferrari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/54003/publications.pdf>

Version: 2024-02-01

102  
papers

12,935  
citations

29994

54  
h-index

30848

102  
g-index

104  
all docs

104  
docs citations

104  
times ranked

10380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Involvement of non-coding RNAs and transcription factors in the induction of Transglutaminase isoforms by ATRA. <i>Amino Acids</i> , 2019, 51, 1273-1288.	1.2	7
2	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	1.8	147
3	<i>IL21R</i> expressing CD14 <sup>+</sup> CD16 <sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclasts. <i>Haematologica</i> , 2017, 102, 773-784.	1.7	36
4	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	15.2	251
5	T cell regulation in HBV-related chronic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 1096-1098.	1.8	14
6	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
7	Effector CD8 <sup>+</sup> T cell-derived interleukin-10 enhances acute liver immunopathology. <i>Journal of Hepatology</i> , 2017, 67, 543-548.	1.8	48
8	Modeling cost-effectiveness and health gains of a universal versus prioritized hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	3.6	25
9	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
10	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. <i>Journal of Medical Virology</i> , 2016, 88, 843-851.	2.5	3
11	Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2016, 65, 509-516.	1.8	142
12	Adaptive immunity in HBV infection. <i>Journal of Hepatology</i> , 2016, 64, S71-S83.	1.8	358
13	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 981-989.	0.7	58
14	Missed treatment in an Italian HBV infected patients cohort: HBV RER. <i>Digestive and Liver Disease</i> , 2016, 48, 1346-1350.	0.4	2
15	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.4	13
16	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. <i>International Journal of Oncology</i> , 2016, 48, 1280-1289.	1.4	10
17	Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. <i>Oncolmmunology</i> , 2016, 5, e1154249.	2.1	37
18	A method for measuring individual research productivity in hospitals: development and feasibility. <i>BMC Health Services Research</i> , 2015, 15, 468.	0.9	13

#	ARTICLE	IF	CITATIONS
19	Bariatric Surgery in Patients with Inflammatory Bowel Disease: An Accessible Path? Report of a Case Series and Review of the Literature. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 185-190.	0.6	40
20	<sc>HBV</sc> and the immune response. <i>Liver International</i> , 2015, 35, 121-128.	1.9	153
21	Natural killer cell phenotype modulation and natural killer/T cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. <i>Hepatology</i> , 2015, 62, 1697-1709.	3.6	73
22	The Role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cerebrospinal Fluids for Screening of Acute Bacterial Meningitis. <i>Clinical Laboratory</i> , 2014, 60, 377-81.	0.2	16
23	Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. <i>Journal of Hepatology</i> , 2013, 59, 221-228.	1.8	34
24	Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. <i>Clinica Chimica Acta</i> , 2013, 418, 59-62.	0.5	17
25	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1385-1395.	0.8	3
26	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5465-5473.	3.2	46
27	Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. <i>Postgraduate Medical Journal</i> , 2013, 89, 294-304.	0.9	49
28	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.	1.1	12
29	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 3766-3776.	3.9	80
30	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. <i>Gut</i> , 2012, 61, 1076-1084.	6.1	51
31	Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. <i>Gut</i> , 2012, 61, 1754-1764.	6.1	387
32	Peginterferon- $\alpha$ does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	1.8	75
33	Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells. <i>Gastroenterology</i> , 2012, 143, 78-87.e3.	0.6	63
34	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2012, 143, 963-973.e9.	0.6	308
35	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	0.6	106
36	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2012, 7, e32493.	1.1	61

#	ARTICLE	IF	CITATIONS
37	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012, 12, 11.	0.8	30
38	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.4	29
39	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. <i>PLoS ONE</i> , 2011, 6, e17232.	1.1	131
40	The Host-Pathogen Interaction during HBV Infection: Immunological Controversies. <i>Antiviral Therapy</i> , 2010, 15, 15-24.	0.6	96
41	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1523-1530.	3.6	105
42	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	9.4	389
43	Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans. <i>PLoS Pathogens</i> , 2010, 6, e1001051.	2.1	72
44	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 138, 682-693.e4.	0.6	416
45	Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. <i>Gastroenterology</i> , 2010, 138, 1931-1942.e2.	0.6	154
46	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1536-1545.	0.6	162
47	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 605-616.	0.2	35
48	The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2008, 134, 1470-1481.	0.6	115
49	Therapeutic Vaccination for Hepatitis C: Can Protective T-Cell Responses Be Restored After Prolonged Antigen Exposure?. <i>Gastroenterology</i> , 2008, 134, 1601-1604.	0.6	7
50	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. <i>Journal of Hepatology</i> , 2008, 48, 548-558.	1.8	113
51	Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon- $\alpha$ 2a/ribavirin therapy. <i>Journal of Hepatology</i> , 2008, 48, 932-938.	1.8	7
52	Corrigendum to "Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment" [J Hepatol 48 (2008) 548-558]. <i>Journal of Hepatology</i> , 2008, 49, 483.	1.8	0
53	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 73-80.	0.6	29
54	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. <i>Journal of Virology</i> , 2008, 82, 10986-10997.	1.5	114

#	ARTICLE	IF	CITATIONS
55	Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. <i>Journal of Immunotherapy</i> , 2008, 31, 271-282.	1.2	72
56	Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. <i>Journal of Virology</i> , 2007, 81, 4215-4225.	1.5	801
57	Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. <i>Vaccine</i> , 2007, 25, 8585-8597.	1.7	160
58	T and B Cells in Hepatitis C Virus Control: What They Do and When They Fail. <i>Gastroenterology</i> , 2007, 132, 801-805.	0.6	6
59	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). <i>Gastroenterology</i> , 2007, 133, 1132-1143.	0.6	57
60	Predicting treatment outcome following 24 weeks peginterferon $\alpha$ -2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , 2007, 45, 258-259.	3.6	6
61	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. <i>Hepatology</i> , 2007, 45, 588-601.	3.6	266
62	Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 45, 1333-1334.	3.6	3
63	Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients. <i>Gastroenterology</i> , 2006, 130, 1098-1106.	0.6	87
64	New perspectives for T-cell-based HCV vaccines. <i>Journal of Hepatology</i> , 2006, 45, 163-165.	1.8	6
65	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. <i>Hepatology</i> , 2006, 43, 602-611.	3.6	35
66	Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. <i>Hepatology</i> , 2006, 44, 126-139.	3.6	176
67	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006, 44, 1617-1625.	3.6	193
68	Interferon (IFN) $\alpha$ -2a Inducible Protein 10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN $\alpha$ -2a and Ribavirin for Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 895-903.	1.9	201
69	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. <i>Cancer Research</i> , 2006, 66, 1139-1146.	0.4	236
70	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. <i>Journal of Virology</i> , 2006, 80, 11398-11403.	1.5	521
71	Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. <i>Hepatology</i> , 2005, 41, 826-831.	3.6	57
72	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2005, 79, 7860-7867.	1.5	386

#	ARTICLE	IF	CITATIONS
73	The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2005, 175, 7519-7529.	0.4	57
74	Heterologous T cell immunity in severe hepatitis C virus infection. <i>Journal of Experimental Medicine</i> , 2005, 201, 675-680.	4.2	134
75	Is Steroid Therapy Needed in the Treatment of Destructive Thyrotoxicosis Induced by $\hat{\iota}$ -Interferon in Chronic Hepatitis C?. <i>Hormone Research in Paediatrics</i> , 2005, 63, 194-199.	0.8	10
76	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	1.8	143
77	Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection. <i>European Journal of Immunology</i> , 2004, 34, 3208-3215.	1.6	14
78	Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. <i>Hepatology</i> , 2004, 40, 289-299.	3.6	13
79	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 102-109.	1.8	66
80	Kinetics of the immune response during HBV and HCV infection. <i>Hepatology</i> , 2003, 38, 4-13.	3.6	227
81	Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 595-605.	1.8	229
82	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. <i>Journal of Virology</i> , 2002, 76, 12423-12434.	1.5	168
83	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV/HCV International Panel. <i>Aids</i> , 2002, 16, 813-828.	1.0	280
84	Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: Functional characterization in patients with chronic hepatitis C. <i>Hepatology</i> , 2002, 35, 1225-1236.	3.6	68
85	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. <i>Hepatology</i> , 2002, 36, 1446-1452.	3.6	66
86	Comparative pathogenesis of HBV and HCV. <i>Virus Research</i> , 2001, 82, 19-23.	1.1	5
87	Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. <i>Hepatology</i> , 2001, 33, 1533-1543.	3.6	40
88	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. <i>Journal of Experimental Medicine</i> , 2000, 191, 1269-1280.	4.2	761
89	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. <i>Hepatology</i> , 1999, 30, 1088-1098.	3.6	150
90	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. <i>Gastroenterology</i> , 1999, 117, 1386-1396.	0.6	331

#	ARTICLE	IF	CITATIONS
91	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. <i>Seminars in Virology</i> , 1996, 7, 23-30.	4.1	8
92	The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. <i>Nature Medicine</i> , 1996, 2, 1104-1108.	15.2	804
93	Hepatitis B virus immunopathology. <i>Seminars in Immunopathology</i> , 1995, 17, 261-81.	4.0	120
94	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. <i>Hepatology</i> , 1994, 19, 286-295.	3.6	238
95	Hepatitis C virus viremia following clinical resolution of acute hepatitis C. <i>Journal of Hepatology</i> , 1994, 20, 666-671.	1.8	49
96	PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. <i>Journal of Hepatology</i> , 1994, 20, 47-56.	1.8	8
97	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. <i>Hepatology</i> , 1994, 19, 286-295.	3.6	21
98	Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. <i>Gastroenterology</i> , 1992, 103, 255-263.	0.6	50
99	Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. <i>Liver</i> , 1992, 12, 94-99.	0.1	17
100	The cellular immune response to nucleocapsid antigens in hepatitis B virus infection. <i>Seminars in Immunopathology</i> , 1990, 12, 25-31.	4.0	10
101	Hepatitis B virus structure and biology. <i>Microbial Pathogenesis</i> , 1989, 6, 311-325.	1.3	78
102	Evaluation of monoclonality of cell lines from sequential dilution assays. <i>Journal of Immunological Methods</i> , 1987, 105, 139-143.	0.6	13